Usual interstitial pneumonia

Usual interstitial pneumonia (UIP) is a form of lung disease characterized by progressive scarring of both lungs. The scarring (fibrosis) involves the pulmonary interstitium (the supporting framework of the lung). UIP is thus classified as a form of interstitial lung disease.

Terminology
The term "usual" refers to the fact that UIP is the most common form of interstitial fibrosis. "Pneumonia" indicates "lung abnormality", which includes fibrosis and inflammation. A term previously used for UIP in the British literature is cryptogenic fibrosing alveolitis (CFA), a term that has fallen out of favor since the basic underlying pathology is now thought to be fibrosis, not inflammation. The term usual interstitial pneumonitis (UIP) has also often been used, but again, the -itis part of that name may overemphasize inflammation.

Signs and symptoms
The typical symptoms of UIP are progressive shortness of breath and cough for a period of months. In some patients, UIP is diagnosed only when a more acute disease supervenes and brings the patient to medical attention.

Causes
The cause of the scarring in UIP may be known (less commonly) or unknown (more commonly). Since the medical term for conditions of unknown cause is "idiopathic", the clinical term for UIP of unknown cause is idiopathic pulmonary fibrosis (IPF). Examples of known causes of UIP include connective tissue diseases (primarily rheumatoid arthritis), drug toxicity, chronic hypersensitivity pneumonitis, asbestosis and Hermansky–Pudlak syndrome.

Diagnosis


UIP may be diagnosed by a radiologist using computed tomography (CT) scan of the chest, or by a pathologist using tissue obtained by a lung biopsy.

Radiology
Radiologically, the main feature required for a confident diagnosis of UIP is honeycomb change in the periphery and the lower portions (bases) of the lungs.

On high-resolution computed tomography (HRCT), the following categories, depending on imaging findings, have been recommended by a collaborative effort by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and the Latin American Thoracic Society:


 * UIP pattern:
 * Honeycombing, with or without peripheral traction bronchiectasis; or bronchiolectasis (dilatation of the terminal bronchioles)
 * Predominantly subpleural and basal
 * Often heterogenous distribution, being occasionally diffuse, and may be asymmetrical

There may be superimposed CT features such as mild ground-glass opacity, reticular pattern and pulmonary ossification.
 * Probable UIP pattern:
 * Predominantly subpleural and basal
 * Often heterogenous distribution
 * Reticular pattern with peripheral traction bronchiectasis or bronchiolectasis
 * There may be mild ground-glass opacity


 * Indeterminate for UIP:
 * Predominantly subpleural and basal
 * Subtle reticular pattern
 * May have mild ground-glass opacity or distortion (“early UIP pattern”)


 * Findings suggestive of another diagnosis, including:
 * Other predominant distribution:
 * Peribronchovascular
 * Perilymphatic
 * Upper or mid-lung
 * Cysts
 * Marked mosaic pattern
 * Predominant ground-glass opacity
 * Profuse lung micronodules
 * Lung nodules, especially centrilobular
 * Consolidation
 * Pleural plaques (indicating asbestosis)
 * Dilated esophagus (indicating connective tissue disease)
 * Distal clavicular erosions (indicating rheumatoid arthritis)
 * Extensive lymph node enlargement
 * Pleural effusion
 * Pleural thickening (indicating connective tissue disease/drugs)

Histology
The histologic hallmarks of UIP, as seen in lung tissue under a microscope by a pathologist, are interstitial fibrosis in a "patchwork pattern", honeycomb change and fibroblast foci (see images below).

Differential diagnosis
The differential diagnosis includes other types of lung disease that cause similar symptoms and show similar abnormalities on chest radiographs. Some of these diseases cause fibrosis, scarring or honeycomb change. The most common considerations include:
 * chronic hypersensitivity pneumonitis
 * non-specific interstitial pneumonia
 * sarcoidosis
 * pulmonary Langerhans cell histiocytosis
 * asbestosis

Management
Oxygen therapy may assist with daily living. In case of idiopathic pulmonary fibrosis, certain medications like nintedanib and pirfenidone can help slow the progression. Lastly, lung transplants may help.

Prognosis
Regardless of cause, UIP is relentlessly progressive, usually leading to respiratory failure and death without a lung transplant. Some patients do well for a prolonged period of time, but then deteriorate rapidly because of a superimposed acute illness (so-called "accelerated UIP"). The outlook for long-term survival is poor. In most studies, the median survival is 3 to 4 years. Patients with UIP in the setting of rheumatoid arthritis have a slightly better prognosis than UIP without a known cause (IPF).

History
UIP, as a term, first appeared in the pathology literature. It was coined by Averill Abraham Liebow.